Daily Judi: Monday, September 12, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
A new malaria vaccine, called R21, tested 80% effective in young children who received a booster shot, exceeding a World Health Organization (WHO) target of 75% efficacy. Developed at Oxford in the United Kingdom, after more trials, the vaccine is expected to be available next year. (BBC News)
Wired reports that there are some who appear immune to coronavirus, and scientists want to unlock their genetic secret.
Duke Health announced that researchers at the Duke Human Vaccine Institute have developed a potential vaccine component that may help the fight against HIV.
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We hope to see you this week, September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
Attending the conference today at the Society for Clinical Data Management in San Antonio, Texas (SCDM2022)? Join AG Mednet's Abraham Gutman in a roundtable discussion on how imaging quality control automation improve endpoint data—Monday, September 12, 2022, from 1:45 to 2:45 p.m.
Our Culture
“We are small enough that we are nimble, so we can prioritize quickly, yet also of significant size that we allocate resources where needed. We truly do a lot. This is my dream job. Judi allows me to have a bigger impact. And we do great work.”
–Jess, Program Manager
About Judi
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
